Sherif Mohammed Gamal

Sherif Mohammed Gamal

Auto-generated profile, based on publicly available information

Sherif Mohammed Gamal

Rheumatology Department, Cairo University , Cairo

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2017 in Lupus
Verified
Journal Article
Closed access
MMM Momtaz
M Momtaz
AFAhmed Fayed
Ahmed Fayed
MWM Wadie
M Wadie
SGS M Gamal
S M Gamal
SGS A Ghoniem
S A Ghoniem
WHW M Hamza
W M Hamza
Aim: We aim to describe the pattern of response to treatment in a cohort of Egyptian lupus nephritis (LN) patients and to define variable prognostic factors. Methods: We retrospectively analyzed records of 928 systemic lupus erythematosus (SLE) patients (898 females, 30 males) with biopsy-confirmed LN seen between 2006 and 2012 at Cairo University hospitals. Results: Our study involved 928 SLE patients with a mean age of 26.25 ± 6.487 years, mean LN duration at time of renal biopsy 6.48 ± 4.27 months, mean SLEDAI 28.22 ± 11.7, and mean follow-up duration of 44.14 ± 17.34 months. Induction treatment achieved remission in 683 patients. Remission was achieved in all 32 patients with class II LN, compared to 651/896 (72.7%) patients in classes III, IV, and V. Induction by intravenous (IV) cyclophosphamide achieved response in 435/575 (75.7%) patients, while induction by mycophenolate mofetil (MMF) resulted in response in 216/321 (67.3%) patients ( p = 0.0068). Nephritic flares were least observed when MMF was used for maintenance (30/239 (12.6%) patients), compared to 71/365 patients (19.5%) ( p = 0.0266) when azathioprine (AZA) was used, and 22/79 patients (27.8%) ( p = 0.002) with IV cyclophosphamide. Class IV LN, high chronicity index, presence of crescents, and interstitial fibrosis in biopsies were all associated with chronic kidney disease (CKD) development eventually ( p < 0.001, p = 0.005, p = 0.012, and p = 0.031, respectively). By the end of the study duration, 305 (32.7%) patients had CKD. Logistic regression detected that high baseline serum creatinine, failure to achieve remission, hypertension, and nephritic flare were the main risk factors for poor renal outcome ( p < 0.001, p < 0.001, p = 0.004, and p < 0.001, respectively). The 5 years’ mortality was 69 (7.4%) patients with sepsis being the main cause of death. Conclusion: IV cyclophosphamide superseded as induction treatment, while MMF was the best maintenance treatment. High serum creatinine, hypertension, and nephritic flare were the main risk factors for poor renal outcome.

9 March 2013 in Zeitschrift für Rheumatologie
Verified
Journal Article
Closed access
PDF file
SFS.M.H. Fadda
S.M.H. Fadda
SGS.M. Gamal
S.M. Gamal
NEN.Y. Elsaid
N.Y. Elsaid
AMA.M. Mohy
A.M. Mohy

1 May 2015 in Joint Bone Spine
Verified
Journal Article
Closed access
TGTamer A Gheita
Tamer A Gheita
SGSherif M. Gamal
Sherif M. Gamal
ISIhab Shaker
Ihab Shaker
HFHussein S. El Fishawy
Hussein S. El Fishawy
RSRehab El Sisi
Rehab El Sisi
SKSanaa A. Kenawy
Sanaa A. Kenawy

5 September 2017 in Immunological Investigations
Verified
Journal Article
Closed access
SGSherif M. Gamal
Sherif M. Gamal
FEFatema T. Elgengehy
Fatema T. Elgengehy
AKAsmaa Kamal
Asmaa Kamal
SBSamah A. El Bakry
Samah A. El Bakry
ESElham Shabaan
Elham Shabaan
IBIman H. Bassyouni
Iman H. Bassyouni
This study aims to assess Growth differentiation factor-15 (GDF-15) level in Scleroderma patients and its relation to disease manifestations. This study included 55 scleroderma patients and 40 age and sex matched healthy volunteers. All patients were subjected to full history taking, thorough clinical examination, and laboratory investigations. GDF-15 serum levels were analyzed in patients and controls using human GDF-15 immunoassay Quantikine ELISA kit. The GDF-15 serum level was significantly higher in Systemic sclerosis (SSc) patients in comparison to healthy control individuals, p-value = 0.004. In addition, the GDF-15 serum levels increased in a significant way in patients with diffuse SSc than those with limited SSc, p = 0.026. Also, we had discovered a significant positive correlation between serum GDF-15 levels and the modified Rodnan score of the SSc patients, r = 0.442, p = 0.001 and a significant association was found between high GDF-15 level and SSc patients with interstitial pulmonary fibrosis (IPF) as compared to healthy controls (p = 0.002). However, no significant difference was found between SSc patients without IPF and healthy subjects regarding GDF-15 level (p = 0.106). GDF-15 serum levels were elevated in patients with SSc and correlated with the extent of skin fibrosis, and it was found to be higher in SSc patients with IPF. Such results may suggest a pivotal role of GDF-15 in fibrotic changes in SSc, and GDF-15 could be a treatment target in SSc patients in future.

31 December 2021 in Archives of Rheumatology
Verified
Journal Article
Open access
PDF file
SGSherif M Gamal
Sherif M Gamal
SMSally Samy Mohamed
Sally Samy Mohamed
MTMarwa Tantawy
Marwa Tantawy
ISIbrahem Siam
Ibrahem Siam
ASAhmed Soliman
Ahmed Soliman
MNMarwa Hassan Niazy
Marwa Hassan Niazy
Objectives: This study aims to examine the frequency and clinical association of lupus-related vasculitis in patients with systemic lupus erythematosus (SLE). Patients and methods: We retrospectively analyzed medical records of a total of 565 SLE patients (42 males, 523 females; mean age: 32.7±9.5 years; range, 13 to 63 years) between January 2017 and February 2020. Demographic, clinical data, and laboratory data and treatment modalities applied were recorded. Lupus-related vasculitis and its different types were documented, and the patients with vasculitis were compared with those without vasculitis. Results: The mean disease duration was 8.9±6.3 years. Vasculitis associated with lupus was found in 191 (33.45%) patients. Cutaneous vasculitis was found in 59.2%, visceral vasculitis in 34.0%, and both in 6.8% of total vasculitis patients. The patients with vasculitis had a longer disease duration (p=0.01), were more likely to have juvenile onset (p=0.002), livedo reticularis (p

1 April 2013 in The Egyptian Rheumatologist
Verified
Journal Article
Open access
BEBassel K. El-Zorkany
Bassel K. El-Zorkany
SGSherif M. Gamal
Sherif M. Gamal
SESherine A. El-Mofty
Sherine A. El-Mofty
Aim of the workTo evaluate frequency and causes of discontinuation of methotrexate (MTX) in a group of Egyptian patients and to identify factors that may increase the incidence of its discontinuation.Patients and methodsOne hundred and fifty seven rheumatoid arthritis (RA) patients with disease duration of at least one year, using or were using methotrexate, were included in this study. All patients were subjected to full history taking including the cause of discontinuation of methotrexate, full detailed clinical examination, laboratory assessment, X-ray hands and assessment of disease activity score (28 joints) (DAS 28) for all RA patients. Patients were divided into two groups according to the current status of MTX use, to identify factors which may increase the incidence of MTX discontinuation.ResultsForty six (29.3%) of the patients stopped MTX due to different causes, hepatic and gastrointestinal side effects were the most common causes of discontinuation, representing together 69.5% of causes of discontinuation. We found significant statistical difference between the two groups regarding disease duration, erythrocyte sedimentation rate (ESR), corticosteroid and non steroidal-anti-inflammatory drug (NSAID) use.ConclusionMTX is a safe and effective drug for RA patients and usually well tolerated, however the use of NSAIDs and corticosteroid may be associated with increased risk of discontinuation of methotrexate especially in patients with long standing disease